Status:
COMPLETED
Long-Term Use Of Pegaptanib In Patients For Subfoveal Choroidal Neovascularization Secondary To Age-Related Macular Degeneration
Lead Sponsor:
Pfizer
Conditions:
Macular Degeneration
Eligibility:
All Genders
Brief Summary
The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in thi...
Detailed Description
All the patients whom an investigator prescribes the first Macugen® should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolled into the...
Eligibility Criteria
Inclusion
- Patients need to be administered Macugen® in order to be enrolled in the surveillance.
Exclusion
- Patients not administered Macugen®.
Key Trial Info
Start Date :
November 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2014
Estimated Enrollment :
3538 Patients enrolled
Trial Details
Trial ID
NCT00845273
Start Date
November 1 2008
End Date
February 1 2014
Last Update
October 2 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.